HomepageCRSP • NASDAQ
add
Crispr Therapeutics AG
$ 48,92
Na sluitingstijd:(0,16%)+0,080
$ 49,00
Gesloten: 18 okt, 19:47:58 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$ 48,29
Dag-range
$ 48,40 - $ 49,24
Jaar-range
$ 37,55 - $ 91,10
Beurswaarde
4,17 mld. USD
Gem. volume
1,03 mln.
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | jun 2024info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 517,00K | -99,26% |
Bedrijfskosten | 19,48 mln. | 2,36% |
Netto inkomsten | -126,41 mln. | -62,60% |
Netto winstmarge | -24,45K | -21.915,39% |
Winst per aandeel | -1,49 | -52,04% |
EBITDA | -146,42 mln. | -62,21% |
Effectief belastingtarief | -1,03% | — |
Balans
Totale activa
Totale passiva
| (USD) | jun 2024info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 2,00 mld. | 13,21% |
Totale activa | 2,34 mld. | 6,50% |
Totale passiva | 358,90 mln. | -5,80% |
Totaal aandelenvermogen | 1,98 mld. | — |
Uitstaande aandelen | 85,17 mln. | — |
Koers-boekwaardeverhouding | 2,07 | — |
Rendement op activa | -15,83% | — |
Rendement op kapitaal | -16,69% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | jun 2024info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -126,41 mln. | -62,60% |
Operationele kasstroom | -95,58 mln. | 28,27% |
Kasstroom uit beleggingen | -126,90 mln. | -158,50% |
Kasstroom uit financiering | -466,00K | -102,78% |
Nettomutatie in liquide middelen | -222,95 mln. | -321,91% |
Vrije kasstroom | -55,64 mln. | 52,07% |
Over
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Opgericht
2013
Hoofdvestiging
Website
Werknemers
407
